Assignee
PRELUDE THERAPEUTICS INC
US·20 granted patents·37 pending applications·24 citations·filing 2018–2025
Top patents by PatentIndex Score
57 records- 0194US11254683B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Feb 22, 2022·3 cites·35 claims
- 0294US11214574B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Jan 4, 2022·3 cites·16 claims
- 0392US11702423B2BRM targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2021·Granted Jul 18, 2023·2 cites·18 claims
- 0492US11673893B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·4 cites·10 claims
- 0591US10570140B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·4 cites·29 claims
- 0690US10711007B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2019·Granted Jul 14, 2020·6 cites·26 claims
- 0787US11939340B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·1 cites·24 claims
- 0885US11208416B2Selective inhibitors of protein arginine methytransterase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Dec 28, 2021·1 cites·37 claims
- 0976US2025367205A1Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1073US2022153747A1Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1172US12459950B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·20 claims
- 1272US2024246993A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1372US2024018158A1Brm targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1471US12486277B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Granted Dec 2, 2025·0 cites·23 claims
- 1571US2025163074A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1669US11078205B2Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Aug 3, 2021·0 cites·26 claims
- 1767US2023174539A1Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1867US2025114354A1Combination treatment regimens - smarca2 degrader with pd-1 inhibitorsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1967US2023357265A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2067US2025074916A1Brm targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2167US2025114353A1Combination Treatment Regimens - SMARCA2 Degrader With GemcitabinePRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2266US2025059175A1Mutant Pi3k-Alpha Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2366US2024352029A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2464US12414953B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Granted Sep 16, 2025·0 cites·70 claims
- 2564US2025161289A1KAT6 Targeting CompoundsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2664US2023010358A1Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) ProteinPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2764US2024150340A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2863US12129262B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Oct 29, 2024·0 cites·29 claims
- 2963US11685744B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Jun 27, 2023·0 cites·54 claims
- 3063US11130769B2Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) proteinPRELUDE THERAPEUTICS INC·Filed 2019·Granted Sep 28, 2021·0 cites·31 claims
- 3162US2024018136A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3261US2025011298A1Crystalline forms of a cdk9 inhibitor and uses thereofPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3361US2024336612A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3460US11524962B2Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2018·Granted Dec 13, 2022·0 cites·23 claims
- 3560US2025361258A1Processes for making prmt5 inhibitorsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3659US2023257394A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3759US2024165244A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3859US2024190886A1BRM Targeting Compounds and Associated Methods of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3959US2024124422A1Mutant pi3k-alpha inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4058US2022251088A1Processes for Making PRMT5 InhibitorsPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4157US2023144528A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4257US2023365576A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4357US2023416240A1Kat6 targeting compoundsPRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4456US2025197418A1Polymorphic Compounds And Uses ThereofPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4555US11622970B2BCL-2 inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2021·Granted Apr 11, 2023·0 cites·20 claims
- 4655US2023212191A1Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) proteinPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4754US2023357275A1Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) proteinPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4853US2023265083A1Heterocycle CDK Inhibitors And Their Use ThereofPRELUDE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4951US12448389B2BRM targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2021·Granted Oct 21, 2025·0 cites·29 claims
- 5049US2025281473A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when PRELUDE THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →